Struggling to find Eylea? Learn why this anti-VEGF eye injection is hard to get in 2026 and what you can do to find it near you.
If your retina specialist recently told you that Eylea is on backorder — or that your next injection might need to be delayed — you're not alone. Thousands of patients across the country have been dealing with Eylea supply issues, and the frustration is real.
Eylea (Aflibercept) is one of the most widely prescribed treatments for serious eye conditions like wet age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion. For many patients, missing even one injection can mean a real risk to their vision.
In this article, we'll break down what Eylea is, why it's been so hard to find, and — most importantly — what you can do about it.
Eylea is the brand name for Aflibercept, a medication that belongs to a class of drugs called VEGF inhibitors (vascular endothelial growth factor inhibitors). It works by blocking certain proteins in your body that cause abnormal blood vessel growth and fluid leakage in the eye.
Eylea is given as an intravitreal injection — a small shot directly into the eye — by a retina specialist or ophthalmologist. It's not something you can pick up at a pharmacy or take at home. Each injection is administered in a doctor's office or outpatient clinic.
Eylea is FDA-approved for:
A newer formulation called Eylea HD (8 mg) was approved in 2023 and allows for longer intervals between injections — up to 16 weeks for some patients.
There are several reasons Eylea has been difficult to access. Here are the main factors:
Eylea is a biologic drug, meaning it's made from living cells rather than simple chemical synthesis. Biologics require specialized manufacturing facilities, strict quality controls, and lengthy production timelines. Even small disruptions in the manufacturing process can lead to supply shortfalls that take weeks or months to resolve.
Eylea has been one of the top-selling drugs in the world, with annual global sales exceeding $9 billion at its peak. Millions of patients depend on regular injections — often every 4 to 8 weeks — creating consistent, high-volume demand that's difficult to ramp up quickly when supply falls short.
While there are other anti-VEGF treatments available (like Lucentis, Avastin, and Vabysmo), Eylea remains the preferred choice for many retina specialists. Biosimilar versions of Aflibercept are still in development and not yet widely available, which means there's no cheaper, interchangeable version to help ease the supply crunch.
Eylea is distributed through specialty pharmacy channels and directly to ophthalmology practices. When supply is constrained, the manufacturer may allocate limited quantities based on historical ordering patterns. This can leave smaller practices or those in rural areas with less access than large retina centers.
If your doctor's office is having trouble getting Eylea, here are some practical steps:
Your doctor is the best person to help you navigate this. They may be able to:
Tools like Medfinder can help you check which providers and practices near you currently have Eylea in stock. This can save you time and help you avoid unnecessary appointment cancellations. Learn more in our guide on how to find Eylea in stock near you.
If you've been on the standard 2 mg Eylea, ask your doctor whether Eylea HD (8 mg) might be appropriate for you. Because it can be given less frequently (every 12 to 16 weeks in some cases), it may be easier to schedule and source.
If cost is also a barrier, Regeneron (the maker of Eylea) offers the Eylea4U copay assistance program and a patient assistance program for uninsured or underinsured patients. You can learn more in our guide on how to save money on Eylea.
The outlook is cautiously optimistic. Regeneron has been working to increase manufacturing capacity, and several Aflibercept biosimilars are moving through the FDA approval pipeline. Once biosimilars become available, they should significantly ease supply constraints and potentially bring down costs.
In the meantime, open communication with your eye care provider is key. Don't skip appointments or delay treatment without talking to your doctor first — untreated conditions like wet AMD can lead to permanent vision loss.
For the latest information on Eylea availability in your area, visit Medfinder. You can also read our Eylea shortage update for 2026 for the most current details.
Finding Eylea in 2026 can be challenging, but it's not impossible. The supply issues are driven by manufacturing complexity, high demand, and limited competition — factors that are slowly improving. By staying in close contact with your retina specialist, exploring alternatives when needed, and using tools like Medfinder, you can stay on top of your treatment and protect your vision.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
